Martin Hyzinski, MD
Hematology & Oncology · Scranton, PANPI 1467446112
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (53.6%), food and beverage and education — rather than concentrated in one kind of arrangement. Novartis accounts for 64.7% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $823 and has fallen 83.9% since, to $133 in 2025.
Across 73 payments — averaging $30.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$124
- AbbVie$104
- EMD Serono, Inc.$86
- Pharmacyclics LLC, An Abbvie Company$78
- Astellas Pharma US Inc$69
- plus $327 from 13 others
Across 3 payments — averaging $2175.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$7K
What the payments were for
- Food & beverage$99845%
- Education$392%
- Other$1,19854%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 27 | $1,446 |
| E.r. Squibb & Sons, L.L.C. | 7 | $124 |
| AbbVie | 5 | $104 |
| EMD Serono, Inc. | 4 | $86 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $78 |
| Astellas Pharma US Inc | 4 | $69 |
| Gilead(2 entities) | 3 | $48 |
| Incyte Corporation | 2 | $35 |
| Johnson & Johnson | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Bristol Myers Squibb | 2 | $29 |
| AstraZeneca | 2 | $29 |
| Sanofi | 1 | $24 |
| Pfizer | 2 | $24 |
| Merck | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
| Myovant Sciences Inc. | 1 | $14 |
| Seagen Inc. | 1 | $13 |
How this compares
$2,234 in reported general payments places this provider in the 55th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 26 | $255,485 |
| RevlimidLenalidomide | 19 | $222,513 |
| JakafiRuxolitinib Phosphate | 12 | $201,055 |
| VenclextaVenetoclax | 12 | $155,555 |
| EliquisApixaban | 17 | $17,161 |
| Anastrozole | 156 | $3,898 |
| Tamoxifen Citrate | 48 | $1,962 |
| Potassium Chloride | 18 | $659 |
| Letrozole | 27 | $563 |
| Acyclovir | 12 | $513 |
| Warfarin Sodium | 28 | $499 |
| Omeprazole | 29 | $326 |
| Famotidine | 17 | $221 |
| Pantoprazole Sodium | 13 | $139 |
| Prednisone | 12 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $78 | $255,48526 claims |
| Bristol Myers SquibbRevlimid | $29 | $222,51319 claims |
| Incyte CorporationJakafi | $35 | $201,05512 claims |
| AbbVieVenclexta | $104 | $155,55512 claims |
| PfizerEliquis | $24 | $17,16117 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $29 | $51312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Scranton
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.